The company projects initial revenue generation from its Sildenafil Cream formulation in Q4 2025, backed by its 503B compounding strategy. Daré plans to provide updates in Q2 2025 on strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback